JAMA

TES-STUDY-P015

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. DOI: 10.1001/jama.2014.8334. PMID: 25038357. NCT01263717. https://pmc.ncbi.nlm.nih.

Study design

Record details

Design: Human clinical and physiological evidence

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P015Human clinical and physiological evidence

JAMA

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. DOI: 10.1001/jama.2014.8334. PMID: 25038357. NCT01263717. https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/(2014). DOI: 10.1001/jama.2014.8334